Introduction
The adoptive transfer of tumor-reactive T lymphocytes, known as adoptive T-cell therapy (ACT), is a potentially curative form of cancer treatment 1 . Akin to passive immunotherapy with monoclonal antibodies (mAbs), ACT is expected to tackle tumors with higher specificity than conventional radiochemotherapy. Adoptively transferred tumor-reactive T cells, however, possess many incremental advantages over mAbs, including direct tumor killing, optimal tissue biodistribution and the capacity to expand and persist long-term after tumor recognition in vivo. Despite its many benefits, the universal application of ACT is challenged , 4-1BB 10 or both 11 , including impressive response rates in case of CD19 targeting on chronic lymphoid leukemia [12] [13] [14] , nonHodgkin lymphoma 11, 14 and acute lymphoid leukemia 15, 16 , have fostered renewed enthusiasm in this form of ACT. Even so, translating the results obtained in B-cell malignancies to other tumor types urgently awaits the validation of CAR targets different from B-cell lineage antigens. Clinical programs are currently investigating CAR-redirection against already known mAb targets, including CD30 in Hodgkin lymphoma 17 , HER2 in solid 18 and brain tumors 19 , the VEGFR-2 in melanoma and renal-cell carcinoma 20 , EGF in glioma 21 , and mesothelin in mesothelioma 22 . Despite intense preclinical research on innovative targets 23, 24 , developing CARs for multiple, rather than single tumor types would be clearly preferable.
Moreover, to avoid immune evasion due to antigen-loss variants, it appears imperative selecting targets that are required for tumor growth in vivo.
The hyaluronate receptor CD44 is a class I membrane glycoprotein over-expressed in hematological and epithelial tumors. CD44 is commonly used as a marker for the prospective identification of cancer stem/initiating cells, possibly playing a crucial role in their phenotype 25 . In mice, CD44 -/-hematopoietic stem cells (HSCs) transduced with the BCR-ABL oncogene fail to initiate leukemia in secondary recipients 26 . By analogy, a CD44-For personal use only. on November 1, 2017 . by guest www.bloodjournal.org From specific mAb has been shown to eradicate human acute myeloid leukemia (AML) stem/initiating cells in xenograft models, partially by inhibiting their homing to the bone marrow 27 . Although appealing, CD44 is expressed ubiquitously, ruling out the opportunity of clinically meaningful CAR redirection. On the contrary, since the expression pattern of its alternatively-spliced isoforms is relatively tumor-restricted 28 , an isoform-specific CAR would have more acceptable safety profile. In particular, the isoform variant 6 (CD44v6 Retroviral and lentiviral constructs. We constructed the CD44v6-specific shRNA by replacing the pri-miR223 upper stem with base-paired CD44v6-specific oligonucleotides maintaining the flanking and loop sequences 35, 36 . The shRNAs were cloned in a thirdgeneration LV including the mOrange marker gene. We derived the CAR scFv from a mutated sequence (BIWA-8) of the humanized CD44v6-specific mAb bivatuzumab. The scFv was cloned with a CD28 signaling domain and the CD3 zeta chain 9 , using the IgG1/CH2CH3
spacer. We expressed the CAR into a SFG-RV backbone or into self-inactivating LV with a PGK bi-directional promoter 37 driving the co-expression of the Herpes-simplex-virus- Transduction and culture conditions. We activated T cells using beads conjugated to mAbs to CD3 and CD28 (ClinExVivo, Invitrogen) or with plastic-bound OKT3 (30 ng/ml, OrthoBiotec) and anti-CD28 mAb (1 microgr/ml, PharMingen). T cells were RV-transduced by two rounds of spinoculation or LV-transduced by overnight incubation. T cells were 
Results

CD44v6 is required for AML and MM engraftment in NSG mice
For verifying the clinical relevance of CD44v6 as a target, we analyzed its surface expression on a panel of leukemic blasts isolated from AML patients (Table S1 ) and of malignant plasma cells from MM patients (Table S2) Figure 1E ). Finally, we silenced CD44v6 expression in primary leukemic blasts and found a significantly reduced capacity to initiate leukemia in NSG mice ( Figure 1F ).
T cells activated with CD3/CD28 beads and transduced with a newly designed
CD44v6.CAR28z mediate potent and specific antileukemia and antimyeloma effects
After verifying the role of CD44v6 in tumor growth in vivo, we constructed a CAR using the scFv from a humanized anti-CD44v6 mAb in frame with the TCR-zeta chain and CD28. The CD44v6.CAR28z was cloned into a RV for transducing primary T cells. For transduction, T cells were activated with CD3/CD28-beads plus IL-7/IL-15 42, 43 . Mean transduction efficiency was 72.0 ± SD 21.6% (Figure 2A) . Importantly, the expansion kinetics of CD44v6.CAR28z 
CD44v6.CAR28z + T cells spare keratinocytes and HSCs, but cause selective monocytopenia in vivo
For predicting potential off-tumor toxicities of CD44v6.CAR28z + T cells, we analyzed
CD44v6 expression by RT-qPCR on a large panel of normal tissues. Detectable CD44v6 expression was only found in the skin and oral mucosa, albeit at considerably lower levels than in primary leukemic blasts ( Figure 4A ). Low-level CD44v6 expression by RT-qPCR
For personal use only. on November 1, 2017. by guest www.bloodjournal.org From was confirmed on primary cultured keratinocytes and evident on basal-layer keratinocytes by skin immunohistochemistry ( Figure 5C ). We therefore specifically addressed whether primary keratinocytes could be recognized in co-culture experiments. Strikingly, at the E:T ratios allowing the potent antitumor effects of CD44v6-targeted T cells, keratinocytes were not killed ( Figure 4B ) and there was no cytokine production ( Figure 4C) . Importantly, selective ablation of T cells was confirmed after CD44v6-specific stimulation ( Figure S5C ). To overcome the hurdle of TK immunogenicity, we alternatively explored the 
CD44v6.CAR28z + T cells co-expressing a suicide gene eradicate autologous leukemia in vivo
For finally validating our strategy in a clinically relevant setting, we proved the feasibility of For
Discussion
In this study, we have preclinically validated a strategy for the safe and effective targeting of We previously showed that the type of activation and the culture conditions for in vitro transduction of T cells greatly contribute to their overall fitness. Activation with CD3/CD28-beads 42 and culture with IL-7/IL-15 46 , instead of activation with OKT3 and IL-2, allow genetically modifying T cells with enhanced persistence and superior antileukemia activity in vivo 43 . More recently, we have found that these properties are due to the preferential transduction of putative stem memory T cells 47 . In this work, we have combined bead activation and IL-7/IL-15 for effective CD44v6-specific CAR redirection of T cells from AML and MM patients. In immunocompromised mice, the kinetics of CD44v6-targeted T cells showed an early expansion phase, and persistence at low levels until sacrifice. In the most stringent and clinically relevant setting of autologous ACT with CD44v6-targeted T cells, this resulted in impressive antitumor effects, as showed in the xenograft model with primary leukemic blasts. Interestingly, bead activation and IL-7/IL-15 were required for maximal antitumor activity, suggesting that optimal "exocostimulation" is a key determinant of antitumor potency, as observed in recent clinical trials 12, 15, 16 .
In clinical trials, tumor responses by CAR-redirected T cells associated with toxicities deriving from off-tumor expression of the target, including a case of fatal lung toxicity when using HER2-targeted T cells 48 and the frequent observation of prolonged B-cell depletion when using CD19-targeted T cells [12] [13] [14] . Despite promising activity against epithelial tumors, controlling the adverse events that may potentially derive from it, i.e. immune incompetence.
Differently from TK, we found that the non-immunogenic suicide gene iC9 enabled full ablation of CD44v6-targeted T cells within hours from exposure to the activating drug and complete rescue from hyper-acute xenogeneic GVHD, suggesting the potential for reverting not only prolonged monocytopenia, but also early and generalized toxicity due to excessive on-target recognition 12, 16 .
In conclusion, given the highly unmet medical need of curative forms of treatment for AML and MM otherwise resistant to conventional radiochemotherapy, we believe that the extensive preclinical validation of suicidal CD44v6-targeted T cells presented in our work warrant their investigation in a first-in-man trial to be conducted in the near future. 
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